Examinando por Autor "Gago Veiga, Ana Beatriz"

Mostrando 1 - 2 de 2
  • Miniatura
    Ítem
    Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response
    (BioMed Central Ltd, 2026-12-01) Muñoz-Vendrell, Albert ; Campoy-Díaz,Sergio; Valín-Villanueva, Paloma; Casas-Limón, Javier; Fernández-Lázaro, Iris; González-García, Nuria; Santos Lasaosa, Sonia; González Osorio, Yésica; Gonzalez-Martinez, Alicia; Campdelacreu Fumadó, Jaume ; Portocarrero-Sánchez, Leonardo; Cano Sánchez, Luis Miguel; García Sánchez, Sonia María; Pérez de la parte, Alba; Morollón, Noemí ; López Bravo, Alba; Mínguez Olaondo, Ane ; Sánchez Soblechero, A.; Lozano Ros, A.; Morales Hernández, Cristian; Andrés López, A.; Layos-Romero, A.; Caronna, Edoardo; Torres Ferrús, Marta; Alpuente Ruiz, Alicia; Pozo Rosich, Patricia; Belvís, Robert; García Azorín, David ; Diaz de Teran, Javier ; Guerrero Peral, Angel Luis ; Gago Veiga, Ana Beatriz ; Huerta Villanueva, Mariano
    Background: Atogepant is approved for migraine prevention and has shown strong efficacy in clinical trials. However, its effectiveness following failure of anti-CGRP monoclonal antibodies (MAbs) has not been evaluated in large real-world populations. Methods: This multicenter observational study conducted across Spanish headache units included adults with migraine who initiated atogepant after failure of ≥ 1 anti-CGRP MAb and had ≥ 3 months of follow-up. Baseline demographic and clinical variables were collected prospectively, with follow-up assessments at months 3 and 6. The primary outcome was the proportion of patients achieving a ≥ 50% reduction in monthly migraine days (MMD) at three months. Secondary outcomes included ≥ 30%, ≥ 75%, and 100% response rates; changes in headache days, pain intensity, acute medication use, and patient-reported outcomes; adverse events; treatment persistence; and factors associated with response. Results: A total of 252 patients were included (mean age 48.9 ± 12 years; 83.3% female; 80.6% with chronic migraine; 45.6% with continuous daily headache). Prior to atogepant, 39.7% had failed one anti-CGRP MAb, 27.0% two, 20.2% three, and 13.1% four. Median baseline MMD was 16, monthly headache days 27, and acute medication days 20. At 3 months, 44.4% achieved a ≥ 30% reduction in MMD, 29.7% ≥50%, and 11.7% ≥75%. Adverse events were reported in 52.5% of patients, most commonly constipation (30%) and nausea (25%). At three months, 26.2% had discontinued treatment (65.1% due to inefficacy, 28.8% due to intolerance). Treatment persistence at 180 days was 61% (95% CI 54 to 69%). A higher number of previously failed MAbs was independently associated with reduced odds of ≥ 50% response (RR 0.79, 95% CI 0.64 to 0.97). Moreover, a higher number of previously failed MAbs was associated with diminished improvements across multiple clinical endpoints, including headache frequency, intensity, acute medication use, and disability measures. Conclusion: Atogepant may represent a viable treatment option for patients with migraine who have failed anti-CGRP MAbs. In this large real-world cohort, approximately one-third of patients achieved a ≥ 50% response, despite a treatment-refractory profile. However, the likelihood of response decreases with a higher number of previously failed MAbs, and mild adverse events are frequent.
  • Miniatura
    Ítem
    Diagnóstico y tratamiento de los trastornos de la presión intracraneal: documento de consenso del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología
    (Spanish Society of Neurology, 2025-01) García Ull, Francisco José; González García, Nuria; Torres Ferrús, Marta; García Azorín, David; Molina Martínez, Francisco José; Beltrán Blasco, Isabel; Santos Lasaosa, Sonia; Latorre, Germán; Gago Veiga, Ana Beatriz; Láinez, José Miguel; Porta Etessam, Jesús; Nieves Castellanos, Candela; Mínguez Olaondo, Ane; López Bravo, Alba; Quintas, Sonia; Morollón, Noemí; Díaz Insa, Samuel; Belvís Nieto, Roberto; Irimia, Pablo
    Los trastornos primarios de la presión intracraneal incluyen la hipertensión intracraneal idiopática y la hipotensión intracraneal espontánea. El diagnóstico y tratamiento de ambas entidades ha presentado un avance destacable en los últimos años, por lo que desde el Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología consideramos necesaria la elaboración de este documento de consenso con la inclusión de algoritmos diagnósticos y terapéuticos para mejorar su manejo en la práctica diaria. Este documento ha sido redactado por un comité de expertos del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología tras realizar una revisión sistemática de la bibliografía, incorporando la experiencia de los participantes y estableciendo unas recomendaciones prácticas con niveles de evidencia y grados de recomendación.